IGF-1 Therapy: What It Is and Why It’s Controversial
If you spend time around athletes, longevity forums, or integrative clinics, you hear about IGF-1 sooner rather than later. Some people speak of it as a fountain of youth. Others warn that it feeds cancer or wrecks blood sugar. Most patients only know they have an IGF-1 number on their lab report and are told it tracks growth hormone status. The truth sits between marketing and fear. To use or dismiss IGF-1 therapy wisely, you need to understand where it fits in the hormone ecosystem, who it is actually meant for, and why most adults should be cautious.
I have worked with hormone therapy for two decades, across traditional endocrinology and functional medicine. I have prescribed testosterone therapy and estrogen and progesterone therapy to thousands, navigated menopause treatment and andropause, and helped manage growth hormone deficiency in adults. IGF-1 is different. It looks simple, but the biology is layered and the clinical use narrower than many believe.
IGF-1 in the body, not in marketing copy
Insulin-like growth factor 1, or IGF-1, is a peptide hormone produced mainly by the liver when stimulated by growth hormone from the pituitary. Most circulating IGF-1 binds to IGF-binding proteins, especially IGFBP-3, which extend its half-life and modulate access to tissues. IGF-1 promotes cell growth, tissue repair, and protein synthesis. In children, it helps bones lengthen and organs develop. In adults, it supports muscle maintenance, bone remodeling, and metabolic flexibility.
Imagine growth hormone as the foreman who signs off on the work. IGF-1 is the crew that actually pours the concrete and frames the house. Measuring IGF-1 offers a steadier look at growth hormone output because growth hormone pulses, while IGF-1 stays more stable over the day. This is why hormone doctors often use IGF-1 as a biomarker during hormone testing and treatment when they check the growth hormone axis.
The key point is this: IGF-1 is normal and necessary. The debate is not about whether IGF-1 is good or bad. The debate is whether giving IGF-1 as a drug makes sense for people who do not have a primary deficiency, and whether nudging levels higher in normal adults helps more than it harms.
The one clear medical use: severe primary IGF-1 deficiency in children
In the United States and many other countries, the only widely accepted indication for IGF-1 therapy is severe primary IGF-1 deficiency in children. The FDA-approved drug is mecasermin, a recombinant human IGF-1. This is not hormone replacement therapy in the way most adults imagine. These are children whose bodies cannot respond to growth hormone and therefore cannot produce adequate IGF-1. Giving growth hormone to these children does not work. Giving IGF-1 can support growth and organ development.
Dosing for mecasermin is done by weight, typically subcutaneous injections twice daily with meals to reduce hypoglycemia risk. Pediatric endocrinologists monitor growth velocity, blood sugar, tonsil size, spine curvature, and intracranial pressure. Families are taught to recognize symptoms like severe headache or visual changes that could signal benign intracranial hypertension. There is nothing casual about this care. It is precise and closely supervised.
Outside of this scenario, IGF-1 therapy slides quickly into gray zones.
Adult growth hormone deficiency is not the same problem
Some adults have true growth hormone deficiency from pituitary disease, surgery, radiation, or genetic conditions. In those cases, the standard treatment is growth hormone therapy, not IGF-1 therapy. The goal is to restore physiologic signaling so the liver produces IGF-1 in a regulated manner, with the buffering effect of IGF-binding proteins. Experienced endocrinologists titrate growth hormone based on IGF-1 targets appropriate for age and sex, lipid changes, body composition, and side effects like edema or joint stiffness. IGF-1 as a lab aids dosing, but giving IGF-1 as the drug rarely enters the conversation.
This distinction matters. Many adults who ask about IGF-1 therapy are really asking for better energy, leaner muscle, sharper cognition, or less joint pain. In adults with documented growth hormone deficiency, improving the growth hormone axis can deliver some of this. The therapy is growth hormone, not IGF-1.
Where the controversy starts: off-label and anti-aging use
The growth hormone and IGF-1 axis attracts attention because it touches so many tissues. That invites off-label exploration. Over the years, studies have looked at IGF-1 in insulin resistance, diabetes complications, neurodegenerative conditions, and frailty syndromes. Some early signals have been intriguing, but large, durable benefits in general adult populations are sparse. Trials in ALS, for example, did New Providence HRT specialists not show consistent clinical improvements, and enthusiasm cooled.
Meanwhile, the anti-aging market promises body recomposition, faster recovery, and better skin with peptides and compounded formulations. People mix IGF-1 variants, growth hormone secretagogues, and testosterone replacement therapy. Results vary wildly. Some individuals feel excellent, drop visceral fat, and swear by the stack. Others bloat, develop carpal tunnel symptoms, or see their fasting glucose drift up. Separating effect from placebo and lifestyle change becomes tricky, especially when programs include improved nutrition, resistance training, and sleep hygiene.
When you add sports to the picture, controversy sharpens. IGF-1 is on the World Anti-Doping Agency prohibited list. Performance gains from enhanced protein synthesis and recovery are genuine enough that doping concerns are justified. Testing is complex because IGF-1 is endogenous and fluctuates hormone therapy with growth hormone, age, and calorie intake.
Safety questions that are not simple yes or no
Every hormone treatment carries trade-offs. With IGF-1, clinicians worry most about hypoglycemia, soft tissue growth in airways, intracranial pressure, edema, and the long horizon risks of promoting cell proliferation.
Hypoglycemia is the most immediate risk when injecting IGF-1, because it increases glucose disposal. Pediatric protocols always pair doses with meals. Adults experimenting off label often underestimate this. I have seen motivated lifters inject in a fasted state to catch an anabolic window, only to end up shaky and diaphoretic 30 minutes later.
Airway tissue can hypertrophy. Enlarged tonsils, snoring, and sleep apnea are well described in pediatric cases. Adults who already teeter on the edge of obstructive sleep apnea can tip over with added soft tissue growth. I am careful with anyone who has daytime somnolence, a thick neck, or a bed partner complaining about loud snoring.
Edema, joint discomfort, and carpal tunnel symptoms reflect water and sodium retention and soft tissue expansion. These effects overlap with growth hormone side effects, which is not surprising given the shared axis. Sometimes they fade with dose reduction. Sometimes they linger.
Cancer risk is the most emotionally charged topic. Epidemiology links higher IGF-1 within normal ranges to increased risks for certain cancers, especially breast, prostate, and colorectal cancers, while lower IGF-1 associates with greater frailty and higher cardiovascular mortality in some cohorts. This U-shaped curve suggests there is an optimal zone, not a simple more is better. Translating associations into clinical guidance is hard. If you already have a pre-malignant lesion, a hormone that encourages growth may push the wrong cells along. If you are sarcopenic and insulin resistant, nudging anabolic tone might help you avoid falls and fractures. Good medicine requires context and humility here.
GH therapy and IGF-1 therapy, side by side
Patients often ask whether taking growth hormone or taking IGF-1 gets them to the same place. They do not act identically. A quick comparison helps set expectations.
Primary target: GH therapy restores pituitary-liver signaling, raising endogenous IGF-1 within physiologic bounds. IGF-1 therapy bypasses the signal, delivering the effector hormone directly. Dosing rhythm: GH is usually once daily subcutaneous at bedtime to mimic physiologic pulses. Mecasermin is typically twice daily with meals, because of hypoglycemia risk. Monitoring: GH is titrated using IGF-1 as a biomarker along with clinical response. IGF-1 therapy requires tight glucose monitoring, ENT checks for tonsillar hypertrophy in younger patients, and attention to headaches or vision changes. Indications: GH is standard for adult GH deficiency and many pediatric GH deficiencies. IGF-1 is approved for severe primary IGF-1 deficiency in children who do not respond to GH. Abuse potential: Both can be misused in anti-aging and athletic settings, but IGF-1 detection and risk of hypoglycemia change the calculus, and both are banned by anti-doping bodies.
In practice, if a hormone specialist identifies adult GH deficiency, growth hormone is the therapy of record. If a child cannot respond to GH, IGF-1 is life changing. There is very little overlap where IGF-1 is clearly preferred in an adult.
Where IGF-1 intersects with common hormone therapies
A large share of adults who ask about IGF-1 are also exploring other hormone therapies. That makes sense, because energy, libido, strength, sleep, and mood do not belong to a single hormone.
Testosterone replacement therapy can increase lean mass, reduce visceral fat, and improve insulin sensitivity. Some of those benefits overlap with what people hope to see from growth hormone and IGF-1. In men with low T, optimizing testosterone is usually more impactful for day to day function, and it carries a more predictable risk profile when managed properly. The interplay matters, though. As body composition improves on TRT, IGF-1 can rise modestly via better growth hormone secretion during deeper sleep and better nutrition.
Estrogen and progesterone therapy in women, especially around menopause, improves sleep architecture, mood, and bone turnover. Better sleep deepens growth hormone pulses, which can raise IGF-1 naturally. Many women who push for anti-aging peptides first need stable estrogen and progesterone under a clinician who understands menopause hormone therapy.
Thyroid hormone normalization often raises energy, improves lipid metabolism, and helps patients train again. Given that resistance training is the single most reliable way to increase IGF-1 signaling within muscle, I always correct thyroid issues before leaning on exotic peptides. That is hormone balancing in the tangible sense, not chasing a lab number.
The best outcomes arrive when a hormone clinic resists the urge to stack everything. Start with the hormones that have proven benefits for the patient’s symptoms and risks, measure honest endpoints, and only then consider advanced options.
What about compounded or “natural” IGF-1 options?
Pharmacies and websites advertise compounded bioidentical IGF-1 sprays, lozenges, or creams. The idea is enticing, but the delivery science is shaky. IGF-1 is a peptide. Absorbing meaningful amounts through the oral mucosa or skin without a specialized delivery system is unlikely. Some products combine deer antler extracts, which contain IGF-1 fragments, marketed as natural hormone therapy. The actual bioavailable dose is unclear, and lot to lot consistency is not guaranteed. Patients sometimes report subjective benefits, usually in the context of other changes to training and diet.

I have a simple rule here. If we are going to alter a powerful hormone axis, do it with a medication that has a known dose, known pharmacokinetics, and medical oversight. If a product is too weak to require that oversight, it is probably too weak to deliver the results that justify the risk and cost.
Testing, targets, and what a sensible evaluation looks like
When patients seek hormone optimization or hormone imbalance treatment, a good starting point is a comprehensive history, an exam, and focused labs. For the growth hormone axis, IGF-1 is the backbone test, with IGFBP-3 sometimes added. Growth hormone itself is less useful as a single blood draw due to pulsatility. Provocation tests exist but are reserved for cases where adult GH deficiency is truly suspected.
Age matters. IGF-1 peaks in the late teens and twenties, then declines gradually. It is normal for a 65-year-old to have a lower IGF-1 than a 25-year-old. The question is whether that lower number aligns with robust function for that person’s context. I do not chase a youthful IGF-1 target in older adults without a clear reason.
Nutrition, sleep, and training move IGF-1 materially. Caloric restriction and low protein intake lower it. Deep sleep and resistance training raise it. Before you think about injections, fix the basics. I have seen a mild increase in protein intake, a shift to earlier bedtimes, and two weekly sessions of compound lifts raise IGF-1 by 20 to 40 percent within a few months. Those same changes improve almost every symptom that people attribute to low growth hormone.
If testing suggests a true pituitary issue, referral to an endocrinologist is appropriate. MRI imaging, pituitary hormone panels, and formal stimulation tests belong in that lane. Endocrine therapy deserves rigor.
Who should be especially careful
Over the years, certain patterns have taught me caution. People with a personal history of cancer, especially hormone sensitive malignancies, warrant a thorough oncology consult before any intervention that could increase proliferative signals. Individuals with untreated obstructive sleep apnea, poorly controlled diabetes, or active proliferative retinopathies are poor candidates for anything that worsens soft tissue growth or destabilizes glucose. And anyone with unexplained headaches, visual changes, or significant edema needs evaluation before considering the anabolic lane.
Here is a practical filter I use when someone asks for IGF-1 therapy in a wellness or longevity context.
History of cancer that is not in durable remission, or strong family syndromes predisposing to cancer. Untreated or severe sleep apnea, significant snoring, or daytime somnolence. Poorly controlled diabetes or frequent hypoglycemia. Active proliferative retinopathy or intracranial hypertension. Lack of basic foundations, such as resistance training twice weekly, 1.2 to 1.6 g/kg/day of protein for most adults, and consistent sleep.
If a person fits any of these, we address the red flag or the foundation first. Many abandon the idea of IGF-1 injections once their base is solid, because their symptoms recede.
Real world cases and lessons
A middle aged strength coach came to my clinic with a shopping list that included IGF-1 LR3 from an online vendor. He had elbow tendinopathy and stalled lifts. His IGF-1 came back midrange for age. Sleep was choppy, and he snored. We held all peptides, ran a home sleep study, and diagnosed moderate sleep apnea. Three months later, on CPAP and a progressive eccentric loading plan, his elbow pain dropped from a daily 6 out of 10 to a 2, and his lifts moved again. IGF-1 as a number had not changed much, but the axis had. His growth hormone pulses recovered with deeper sleep.
A woman in her early fifties, navigating perimenopause, wanted energy and less abdominal fat. Her IGF-1 was low normal for age, fasting insulin high. We started menopause relief treatment with transdermal estradiol and oral progesterone, tuned her thyroid from borderline high TSH to a tighter range, and added progressive resistance training. Six months later, she lost 12 pounds of fat by DEXA, gained 4 pounds of lean mass, and her IGF-1 rose modestly. She never needed peptides. Her hormone optimization came from targeted HRT and lifestyle.
These cases are not arguments against IGF-1. They illustrate that when people ask for IGF-1, they are often asking for function. The shortest road to function rarely begins with an injectable growth factor.
What a careful plan could look like if IGF-1 is on the table
There are adults who might reasonably consider IGF-1 under specialist care. This is uncommon, but scenarios occur. For example, a research protocol enrolling sarcopenic older adults with insulin resistance may administer low dose IGF-1 with strict monitoring. Another example is a rare adult with clear GH pathway resistance who does not tolerate GH.
If you find yourself at that edge, the plan should include informed consent that covers known and unknown risks, a trial period with measurable endpoints, and frequent monitoring. Doses should be the lowest required to meet those endpoints. Meals must accompany injections to prevent hypoglycemia. Baseline and interval eye exams, glucose checks, sleep assessments, and head and neck exams should be part of the package. A hormone specialist, not a sales consultant, should run the program.
Compounded hormone therapy that tries to mimic mecasermin may be offered in some clinics. I advise caution. Use regulated products when available, and if they are not available for your indication, ask why. Sometimes the lack of approval reflects risks that have not been solved, not a conspiracy against wellness.
A note on expectations and timelines
Even when you select the right therapy, time horizons matter. Muscle hypertrophy responds over weeks. Tendon and collagen remodeling stretch into months. Bone density responds over years. IGF-1 can accelerate protein synthesis, but it will not replace load. Hormone rebalancing should amplify the effect of training and nutrition, not stand in for them.
Patients who thrive in hormone wellness programs learn to separate what the hormone should do from what only disciplined behavior can do. Your hormone doctor should help you set these expectations. If your first visit focuses more on a menu of injectables than on your sleep, training, stress, and diet, find another clinic.
Practical takeaways for patients considering the IGF-1 conversation
If you see IGF-1 therapy advertised as a simple route to youth, be skeptical. Its medical home is narrow and pediatric. In healthy or moderately unwell adults, the benefits are unproven at scale, and the risks are not trivial. For most adults seeking hormone health treatment, better options come first. Testosterone optimization in confirmed hypogonadism, estrogen and progesterone therapy for menopausal symptoms, thoughtful thyroid hormone replacement when indicated, and a structured program of resistance training will move the needle more safely and reliably.
If you work with a hormone specialist who suggests IGF-1, ask what specific outcome you are measuring, what dose and schedule will be used, how hypoglycemia will be prevented, and what the off-ramps are if side effects emerge. Good endocrine treatment always includes these details.
Finally, remember that youthfulness is not a single lab value. It is a stack of habits supported by targeted therapies where evidence is strongest. IGF-1 is a powerful molecule, essential to life and growth. It is also a narrow tool, useful in the right hands for the right patient. The controversy comes from trying to turn a narrow tool into a universal solution. That is not how hormones work, and not how wise medicine is practiced.